• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

2.630 -0.130 (-4.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 Next >
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
December 06, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
November 26, 2025
From Schall Law
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
November 19, 2025
From Schall Law
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
November 11, 2025
From The Schall Law Firm
Via Business Wire
News headline image
Prelude Therapeutics Announces Strategic Business Update
November 04, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
November 04, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
November 03, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
October 17, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
June 02, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 06, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
May 01, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Announces Presentations at 2025 AACR Annual Meeting
April 25, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
March 10, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
March 05, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
December 11, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
November 27, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
October 24, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
October 09, 2024
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
September 13, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
September 09, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
July 09, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
June 03, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
May 09, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap